Skip to main content

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Alzheimer & Dementia Related Cognitive Disorders Topic Center

marc agronin md
Blog
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
quiz
Quiz
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
The US Food and Drug Administration headquarters sign.
07/02/2024
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug...
07/02/2024
Psych Congress Network
Alzheimer and cognitive decline graphic
News
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
Lecanemab AD Treatment Could Have Low Eligibility
News
06/19/2024
Evi Arthur
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
From Neurology
Sleep apnea during REM cycle
News
05/20/2024
Jolynn Tumolo
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive...
05/20/2024
Neurology
From Neurology
Genetic Variant Appears to Protect Against Alzheimer Disease in At-Risk Individuals
News
04/29/2024
Jolynn Tumolo
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease...
04/29/2024
Neurology
From Neurology
Illustration of the brain
News
04/22/2024
Jolynn Tumolo
Antipsychotic use in patients with dementia is associated with an increased risk for a handful of serious adverse outcomes, including pneumonia, acute kidney injury, venous thromboembolism, and stroke.
Antipsychotic use in patients with dementia is associated with an increased risk for a handful of serious adverse outcomes, including pneumonia, acute kidney injury, venous thromboembolism, and stroke.
Antipsychotic use in patients...
04/22/2024
Psych Congress Network
Doctors examine brain scans
News
03/04/2024
Jolynn Tumolo
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients...
03/04/2024
Neurology
From Neurology
Brain scan
News
03/01/2024
Meagan Thistle
Recent study reveals significant insights into the structural brain changes associated with aging in individuals without diagnosed cognitive impairment.
Recent study reveals significant insights into the structural brain changes associated with aging in individuals without diagnosed cognitive impairment.
Recent study reveals significant...
03/01/2024
Psych Congress Network
An elderly patient with Alzheimer disease looks up at their caregiver
02/16/2024
Meagan Thistle
Otsuka Pharmaceutical Co., Ltd. unveiled the topline results of the phase 3 clinical trial of AVP-786 in treating agitation associated with dementia due to Alzheimer disease.
Otsuka Pharmaceutical Co., Ltd. unveiled the topline results of the phase 3 clinical trial of AVP-786 in treating agitation associated with dementia due to Alzheimer disease.
Otsuka Pharmaceutical Co., Ltd....
02/16/2024
Psych Congress Network

Quizzes

quiz
Quiz
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
Why do hurricanes increase mortality risk in ADRD populations?
Quiz
04/04/2023
Do you remember this study?
Do you remember this study?
Do you remember this study?
04/04/2023
Psych Congress Network
Four pencils with their erasers spelling out "quiz."
Quiz
09/28/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
09/28/2022
Psych Congress Network
quiz
Quiz
08/07/2024
In bipolar disorder, how do norepinephrine (also referred to as noradrenaline) levels impact episodes of mania? Take the quiz!
In bipolar disorder, how do norepinephrine (also referred to as noradrenaline) levels impact episodes of mania? Take the quiz!
In bipolar disorder, how do...
08/07/2024
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
Expert Insights Quiz
07/22/2024
Hone your telehealth practice and knowledge with this quiz!
Hone your telehealth practice and knowledge with this quiz!
Hone your telehealth practice...
07/22/2024
Psych Congress Network
How many symptoms must be present in order to diagnose adult ADHD?
Quiz
07/17/2024
Challenge your diagnostic knowledge!
Challenge your diagnostic knowledge!
Challenge your diagnostic...
07/17/2024
Psych Congress Network
How easy is it to switch patients from olanzapine to olanzapine samidorphan?
Quiz
07/16/2024
Do you remember this insight from Dr Jain?
Do you remember this insight from Dr Jain?
Do you remember this insight...
07/16/2024
Psych Congress Network
quiz
Quiz
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
A cartoon illustration of a brain with two medical professionals standing on either side; one holds up a magnifying glass to the brain
Quiz
07/02/2024
Do you know what the DSM-5-TR says on this topic? Find out with this quiz!
Do you know what the DSM-5-TR says on this topic? Find out with this quiz!
Do you know what the DSM-5-TR...
07/02/2024
Psych Congress Network
quiz
Quiz
06/28/2024
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a...
06/28/2024
Psych Congress Network
quiz
Quiz
06/21/2024
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic...
06/21/2024
Psych Congress Network
an illustrated head in profile with brain, against a pink background.
Quiz
06/18/2024
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the...
06/18/2024
Psych Congress Network
Can stimulant use increase risk of heart damage in young adults with ADHD?
Quiz
06/17/2024
Time for a pop quiz!
Time for a pop quiz!
Time for a pop quiz!
06/17/2024
Psych Congress Network

Insights

marc agronin md
Blog
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Leslie Citrome, MD, MPH.
Videos
11/09/2023

Featuring Leslie Citrome, MD, MPH

Featuring Leslie Citrome, MD, MPH ...
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals...
11/09/2023
Psychiatry & Behavioral Health
Dr Paul Schulz
Videos
10/16/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/16/2023
Psych Congress Network
Dr Paul Schulz
Videos
09/22/2023

With Paul Schulz, MD

With Paul Schulz, MD
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
09/22/2023
Psych Congress Network
Dr Paul Schulz
Videos
09/11/2023

With Paul Schulz, MD 

With Paul Schulz, MD 
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the...
09/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
08/11/2023

Featuring Marc Agronin, MD

Featuring Marc Agronin, MD
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych...
08/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
07/20/2023

Featuring Marc Agronin, MD

Featuring Marc Agronin, MD
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric...
07/20/2023
Psych Congress Network
Marc Agronin, MD.
Blog
08/30/2022
Marc Agronin, MD
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Douglas_Scharre_alzheimers_aducanumab
Videos
08/27/2021
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre,...
08/27/2021
Psych Congress Network
Improving Cognition in Patients With Alzheimer’s Disease
Videos
11/11/2020
In this video, geriatric psychiatrist Marc E. Agronin, MD, discusses medications that may improve cognition in patients with Alzheimer's disease.
In this video, geriatric psychiatrist Marc E. Agronin, MD, discusses medications that may improve cognition in patients with Alzheimer's disease.
In this video, geriatric...
11/11/2020
Psych Congress Network
Nishi Bhopal, MD
Q&As
08/08/2024
Nishi Bhopal, MD, clarifies 5 common misconceptions about sleep medicine for mental health care practice.
Nishi Bhopal, MD, clarifies 5 common misconceptions about sleep medicine for mental health care practice.
Nishi Bhopal, MD, clarifies 5...
08/08/2024
Psych Congress Network
Julie Carbray, PhD, APRN
Videos
08/06/2024
In this video, Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, offers practical guidance for telehealth providers screening for, diagnosing, and treating attention-deficit/hyperactivity disorder (ADHD) in pediatric and/or adult patients. 
In this video, Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, offers practical guidance for telehealth providers screening for, diagnosing, and treating attention-deficit/hyperactivity disorder (ADHD) in pediatric and/or adult patients. 
In this video, Julie Carbray,...
08/06/2024
Psych Congress Network
Julie Carbray, PhD
Videos
08/06/2024
Join Julie Carbray, PhD, APRN, clinical professor of psychiatry and nursing at the University of Illinois Chicago, as she delves into the best practices for diagnosing attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder.
Join Julie Carbray, PhD, APRN, clinical professor of psychiatry and nursing at the University of Illinois Chicago, as she delves into the best practices for diagnosing attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder.
Join Julie Carbray, PhD, APRN,...
08/06/2024
Psych Congress Network
Julie Carbray, PhD
Videos
07/31/2024
Join Dr Julie Carbray as she delves into the recent advancements and emerging therapies in bipolar disorder treatment.
Join Dr Julie Carbray as she delves into the recent advancements and emerging therapies in bipolar disorder treatment.
Join Dr Julie Carbray as she...
07/31/2024
Psych Congress Network
marc agronin md
Blog
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Drs Podesta and Carbray
Podcasts
07/22/2024
Drs Podesta and Carbray examine available treatments, recommended strategies, and how clinicians can better communicate with patients with this comorbidity.
Drs Podesta and Carbray examine available treatments, recommended strategies, and how clinicians can better communicate with patients with this comorbidity.
Drs Podesta and Carbray examine...
07/22/2024
Psych Congress Network
Nishi Bhopal, MD
Q&As
07/16/2024
Nishi Bhopal, MD, discusses how mental health clinicians can more closely incorporate sleep disorder screening, diagnosis, and treatment into their practices.
Nishi Bhopal, MD, discusses how mental health clinicians can more closely incorporate sleep disorder screening, diagnosis, and treatment into their practices.
Nishi Bhopal, MD, discusses how...
07/16/2024
Psych Congress Network
Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
07/15/2024
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN,...
07/15/2024
Psych Congress Network
Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
07/15/2024
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia.
Amber Hoberg, MSN, APRN,...
07/15/2024
Psych Congress Network

Practice Tools

marc agronin md
Blog
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
quiz
Quiz
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
The US Food and Drug Administration headquarters sign.
07/02/2024
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.
The US Food and Drug...
07/02/2024
Psych Congress Network
Alzheimer and cognitive decline graphic
News
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
Lecanemab AD Treatment Could Have Low Eligibility
News
06/19/2024
Evi Arthur
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
Sleep apnea during REM cycle
News
05/20/2024
Jolynn Tumolo
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive...
05/20/2024
Neurology
Genetic Variant Appears to Protect Against Alzheimer Disease in At-Risk Individuals
News
04/29/2024
Jolynn Tumolo
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease...
04/29/2024
Neurology
Illustration of the brain
News
04/22/2024
Jolynn Tumolo
Antipsychotic use in patients with dementia is associated with an increased risk for a handful of serious adverse outcomes, including pneumonia, acute kidney injury, venous thromboembolism, and stroke.
Antipsychotic use in patients with dementia is associated with an increased risk for a handful of serious adverse outcomes, including pneumonia, acute kidney injury, venous thromboembolism, and stroke.
Antipsychotic use in patients...
04/22/2024
Psych Congress Network
Doctors examine brain scans
News
03/04/2024
Jolynn Tumolo
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients...
03/04/2024
Neurology
Brain scan
News
03/01/2024
Meagan Thistle
Recent study reveals significant insights into the structural brain changes associated with aging in individuals without diagnosed cognitive impairment.
Recent study reveals significant insights into the structural brain changes associated with aging in individuals without diagnosed cognitive impairment.
Recent study reveals significant...
03/01/2024
Psych Congress Network
Nishi Bhopal, MD
Q&As
08/08/2024
Nishi Bhopal, MD, clarifies 5 common misconceptions about sleep medicine for mental health care practice.
Nishi Bhopal, MD, clarifies 5 common misconceptions about sleep medicine for mental health care practice.
Nishi Bhopal, MD, clarifies 5...
08/08/2024
Psych Congress Network
A health care professional reviews paperwork while sitting at a desk in front of a computer
News
08/07/2024
Adding internet and phone support to a family practitioner review for possible discontinuation of long-term antidepressants provided small additional benefits.
Adding internet and phone support to a family practitioner review for possible discontinuation of long-term antidepressants provided small additional benefits.
Adding internet and phone...
08/07/2024
Psych Congress Network
quiz
Quiz
08/07/2024
In bipolar disorder, how do norepinephrine (also referred to as noradrenaline) levels impact episodes of mania? Take the quiz!
In bipolar disorder, how do norepinephrine (also referred to as noradrenaline) levels impact episodes of mania? Take the quiz!
In bipolar disorder, how do...
08/07/2024
Psych Congress Network
Julie Carbray, PhD, APRN
Videos
08/06/2024
In this video, Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, offers practical guidance for telehealth providers screening for, diagnosing, and treating attention-deficit/hyperactivity disorder (ADHD) in pediatric and/or adult patients. 
In this video, Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, offers practical guidance for telehealth providers screening for, diagnosing, and treating attention-deficit/hyperactivity disorder (ADHD) in pediatric and/or adult patients. 
In this video, Julie Carbray,...
08/06/2024
Psych Congress Network
08/06/2024
Hi, I'm Julie Carbray, nurse practitioner and clinical professor of psychiatry and nursing at the University of Illinois Chicago, department of psychiatry and college of nursing.  The best methods to determine whether your patient has...
Hi, I'm Julie Carbray, nurse practitioner and clinical professor of psychiatry and nursing at the University of Illinois Chicago, department of psychiatry and college of nursing.  The best methods to determine whether your patient has...
Hi, I'm Julie Carbray, nurse...
08/06/2024
Psych Congress Network
Julie Carbray, PhD
Videos
08/06/2024
Join Julie Carbray, PhD, APRN, clinical professor of psychiatry and nursing at the University of Illinois Chicago, as she delves into the best practices for diagnosing attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder.
Join Julie Carbray, PhD, APRN, clinical professor of psychiatry and nursing at the University of Illinois Chicago, as she delves into the best practices for diagnosing attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder.
Join Julie Carbray, PhD, APRN,...
08/06/2024
Psych Congress Network
Person using a mobile phone
SPONSORED
08/05/2024
“ADHDers” are actively searching for answers around “learning with ADHD," with a 135% INCREASE in searches about “learning with ADHD” since 2019.
“ADHDers” are actively searching for answers around “learning with ADHD," with a 135% INCREASE in searches about “learning with ADHD” since 2019.
“ADHDers” are actively searching...
08/05/2024
Psych Congress Network
Kids getting on school bus
SPONSORED
08/05/2024
Access this helpful resource to examine what some of your ADHD patients may be facing this back-to-school season.
Access this helpful resource to examine what some of your ADHD patients may be facing this back-to-school season.
Access this helpful resource to...
08/05/2024
Psych Congress Network
Adults standing with a graph in the background
SPONSORED
08/05/2024
Data update including long-term safety and efficacy data for adult patients with ADHD 18 years of age and older.
Data update including long-term safety and efficacy data for adult patients with ADHD 18 years of age and older.
Data update including long-term...
08/05/2024
Psych Congress Network

News Articles

Alzheimer and cognitive decline graphic
News
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
Lecanemab AD Treatment Could Have Low Eligibility
News
06/19/2024
Evi Arthur
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
Sleep apnea during REM cycle
News
05/20/2024
Jolynn Tumolo
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive sleep apnea (OSA) events during REM sleep is associated with worse verbal memory impairment in older adults at risk for Alzheimer disease (AD), according to a study published online in the journal Alzheimer’s...
The severity of obstructive...
05/20/2024
Neurology
Genetic Variant Appears to Protect Against Alzheimer Disease in At-Risk Individuals
News
04/29/2024
Jolynn Tumolo
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease the odds of developing Alzheimer disease (AD) by as much as 70% in people who carry the APOE ε4 allele, which is known to significantly increase AD risk. Researchers published the findings online in Acta...
A genetic variant may decrease...
04/29/2024
Neurology
Illustration of the brain
News
04/22/2024
Jolynn Tumolo
Antipsychotic use in patients with dementia is associated with an increased risk for a handful of serious adverse outcomes, including pneumonia, acute kidney injury, venous thromboembolism, and stroke.
Antipsychotic use in patients with dementia is associated with an increased risk for a handful of serious adverse outcomes, including pneumonia, acute kidney injury, venous thromboembolism, and stroke.
Antipsychotic use in patients...
04/22/2024
Psych Congress Network
Doctors examine brain scans
News
03/04/2024
Jolynn Tumolo
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients with amyotrophic lateral sclerosis (ALS) had neuropathological signs of frontotemporal dementia, according to study results published in Brain.
More than a third of patients...
03/04/2024
Neurology
Brain scan
News
03/01/2024
Meagan Thistle
Recent study reveals significant insights into the structural brain changes associated with aging in individuals without diagnosed cognitive impairment.
Recent study reveals significant insights into the structural brain changes associated with aging in individuals without diagnosed cognitive impairment.
Recent study reveals significant...
03/01/2024
Psych Congress Network
A doctor examines MRI scans of a brain.
News
02/07/2024
Jolynn Tumolo
After promising findings in a small, open-label, phase 1 pilot study of low-dose interleukine-2 (IL-2) immunotherapy in patients with Alzheimer disease (AD), researchers are proceeding with a double-blinded, randomized, placebo-controlled,...
After promising findings in a small, open-label, phase 1 pilot study of low-dose interleukine-2 (IL-2) immunotherapy in patients with Alzheimer disease (AD), researchers are proceeding with a double-blinded, randomized, placebo-controlled,...
After promising findings in a...
02/07/2024
Neurology
Hearing Loss Prevention Could Delay, Prevent Dementia Onset
News
01/29/2024
Evi Arthur
Hearing aids could delay or prevent dementia onset, according to a population-based cohort study recently published in the journal JAMA Otolaryngology Head & Neck Surgery.
Hearing aids could delay or prevent dementia onset, according to a population-based cohort study recently published in the journal JAMA Otolaryngology Head & Neck Surgery.
Hearing aids could delay or...
01/29/2024
Psych Congress Network
Excessive TV Use Could Raise Risk of Dementia, PD, and Depression
News
01/15/2024
Evi Arthur
Excessive TV watching was associated with an increased risk of dementia, Parkinson disease (PD), and depression, according to recent study results.
Excessive TV watching was associated with an increased risk of dementia, Parkinson disease (PD), and depression, according to recent study results.
Excessive TV watching was...
01/15/2024
Neurology
A health care professional reviews paperwork while sitting at a desk in front of a computer
News
08/07/2024
Adding internet and phone support to a family practitioner review for possible discontinuation of long-term antidepressants provided small additional benefits.
Adding internet and phone support to a family practitioner review for possible discontinuation of long-term antidepressants provided small additional benefits.
Adding internet and phone...
08/07/2024
Psych Congress Network
Meta-Analysis Characterizes Neural Activation Differences in ADHD and ASD
News
08/05/2024
A meta-analysis of 243 studies found both similar and different neural activations during task completion in participants with ADHD and ASD compared with typically developing control subjects. Researchers published their findings in the...
A meta-analysis of 243 studies found both similar and different neural activations during task completion in participants with ADHD and ASD compared with typically developing control subjects. Researchers published their findings in the...
A meta-analysis of 243 studies...
08/05/2024
Psych Congress Network
nursing home care
News
08/02/2024
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light...
08/02/2024
Psych Congress Network
A brain puzzle against an orange background
News
08/01/2024
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension...
08/01/2024
Psych Congress Network
Doctor and patient
News
08/01/2024
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing...
08/01/2024
Psych Congress Network
Continuing ADHD Treatment During Pregnancy May Help Patients Better Manage OUD
News
07/31/2024
Pregnant patients with comorbid ADHD and OUD who remain on their ADHD medications throughout pregnancy are more likely to adhere to OUD treatment and less likely to overdose than patients who stop taking ADHD medication, according to results...
Pregnant patients with comorbid ADHD and OUD who remain on their ADHD medications throughout pregnancy are more likely to adhere to OUD treatment and less likely to overdose than patients who stop taking ADHD medication, according to results...
Pregnant patients with comorbid...
07/31/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
07/24/2024
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
News
07/24/2024
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug...
07/24/2024
Psych Congress Network
FDA building sign
News
07/23/2024
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug...
07/23/2024
Psych Congress Network
One in 7 Patients Experience Antidepressant Discontinuation Symptoms, Study Says
News
07/22/2024
Including non-specific effects, approximately 15% or 1 in 6 to 7 patients experience antidepressant discontinuation symptoms, according to recent systematic review and meta-analysis results published in The Lancet Psychiatry. 
Including non-specific effects, approximately 15% or 1 in 6 to 7 patients experience antidepressant discontinuation symptoms, according to recent systematic review and meta-analysis results published in The Lancet Psychiatry. 
Including non-specific effects,...
07/22/2024
Psych Congress Network

Posters

In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...
10/26/2023
Routine implementation of pharmacogenomic testing for mental health and other conditions treated in primary care may require overcoming barriers such as cost to the patient and knowledge ...
10/26/2023
Valbenazine is indicated for once-daily treatment of tardive dyskinesia (TD), a movement disorder associated with prolonged antipsychotic exposure. Data from 3 long-term studies (KINECT™-...
10/26/2023
Veterans Intensive Primary Care Mental Health Integration Bootcamp (VIP Bootcamp): An upstream solution to Mental Health(MH) access issues within the VA system
10/26/2023
Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...
10/26/2023
Catatonia is a psychomotor syndrome with well-defined clinical characteristics, although the neurological mechanisms involved remain unknown. In this study, we report a case of a patient ...
10/26/2023
This study examined the utilization pattern of augmentation with atypical antipsychotics after partial or no response to antidepressants in patients with MDD. The antidepressant prescript...
10/26/2023
The Rapid Mood Screener (RMS) is a self-administered screening tool to help differentiate bipolar I disorder from major depressive disorder. Cases were identified from a primary care sett...
10/26/2023
This case report discusses the safety and efficacy of VMAT2 inhibitors in treating antipsychotic induced tardive dyskinesia in adults >55 years old. It also highlights the increased ri...
10/26/2023
The subject matter of the poster includes a case report of a patient with treatment refractory catatonia whose condition rapidly improved following a game of chess, one of the patient's k...
10/26/2023

Advertisement

Advertisement

Advertisement

Advertisement